background
recent
cluster
pneumonia
case
wuhan
china
caus
novel
betacoronaviru
novel
coronaviru
report
epidemiolog
clinic
laboratori
radiolog
characterist
treatment
clinic
outcom
patient
patient
suspect
admit
design
hospit
wuhan
prospect
collect
analys
data
patient
laboratoryconfirm
infect
realtim
rtpcr
nextgener
sequenc
data
obtain
standardis
data
collect
form
share
intern
sever
acut
respiratori
emerg
infect
consortium
electron
medic
record
research
also
directli
commun
patient
famili
ascertain
epidemiolog
symptom
data
outcom
also
compar
patient
admit
intens
care
unit
icu
huanan
seafood
market
one
famili
cluster
found
common
symptom
onset
ill
fever
patient
cough
myalgia
fatigu
less
common
symptom
sputum
product
headach
three
haemoptysi
two
diarrhoea
one
dyspnoea
develop
patient
median
time
ill
onset
dyspnoea
day
iqr
patient
lymphopenia
patient
pneumonia
abnorm
find
chest
ct
complic
includ
acut
respiratori
distress
syndrom
rnaaemia
six
acut
cardiac
injuri
five
secondari
infect
four
patient
admit
icu
six
die
compar
nonicu
patient
icu
patient
higher
plasma
level
gscf
interpret
infect
caus
cluster
sever
respiratori
ill
similar
sever
acut
respiratori
syndrom
coronaviru
associ
icu
admiss
high
mortal
major
gap
knowledg
origin
epidemiolog
durat
human
transmiss
clinic
spectrum
diseas
need
fulfil
futur
studi
coronavirus
envelop
nonseg
positivesens
rna
virus
belong
famili
coronavirida
order
nidoviral
broadli
distribut
human
mammal
although
human
coronaviru
infect
mild
epidem
two
betacoronavirus
sever
acut
respiratori
syndrom
coronaviru
sarscov
middl
east
respiratori
syndrom
coronaviru
merscov
caus
cumul
case
past
two
decad
mortal
rate
sarscov
merscov
coronavirus
alreadi
identifi
might
tip
iceberg
potenti
novel
sever
zoonot
event
reveal
decemb
seri
pneumonia
case
unknown
caus
emerg
wuhan
hubei
china
clinic
present
greatli
resembl
viral
pneumonia
deep
sequenc
analysi
lower
respiratori
tract
sampl
indic
novel
coronaviru
name
novel
coronaviru
thu
far
confirm
case
includ
healthcar
worker
identifi
wuhan
sever
export
case
confirm
provinc
china
thailand
japan
south
korea
usa
aim
describ
epidemiolog
clinic
laboratori
radiolog
characterist
treatment
outcom
patient
confirm
infect
compar
clinic
featur
intens
care
unit
icu
nonicu
patient
hope
studi
find
inform
global
commun
emerg
novel
coronaviru
clinic
featur
follow
pneumonia
case
unknown
caus
report
wuhan
consid
share
histori
exposur
huanan
seafood
market
across
patient
epidemiolog
alert
releas
local
health
author
dec
market
shut
jan
meanwhil
suspect
case
fever
dri
cough
transfer
design
hospit
start
dec
expert
team
physician
epidemiologist
virologist
govern
offici
soon
form
alert
sinc
caus
unknown
onset
emerg
infect
diagnosi
pneumonia
unknown
caus
wuhan
base
clinic
characterist
chest
imag
rule
common
bacteri
viral
pathogen
caus
pneumonia
suspect
patient
isol
use
airborn
precaut
design
hospit
jin
yintan
hospit
wuhan
china
fittest
mask
airborn
precaut
aerosolgener
procedur
taken
studi
approv
nation
health
commiss
china
ethic
commiss
jin
yintan
hospit
written
inform
consent
waiv
ethic
commiss
design
hospit
emerg
infecti
diseas
local
centr
diseas
control
prevent
collect
respiratori
blood
faec
specimen
ship
design
authorit
laboratori
detect
pathogen
nhc
key
laboratori
system
biolog
pathogen
christoph
laboratori
beij
china
novel
coronaviru
name
isol
lower
respiratori
tract
specimen
diagnost
test
viru
develop
soon
suspect
case
patient
confirm
infect
presenc
respi
ratori
specimen
detect
nextgener
se
quenc
realtim
rtpcr
method
primer
probe
target
envelop
gene
cov
use
sequenc
follow
forward
primer
revers
primer
probe
condit
amplif
min
min
follow
cycl
initi
investig
includ
complet
blood
count
coagul
profil
serum
biochem
test
includ
renal
liver
function
creatin
kinas
lactat
dehydrogenas
electrolyt
respiratori
specimen
includ
nasal
pharyng
swab
bronchoalveolar
lavag
fluid
sputum
bronchial
aspir
test
common
virus
includ
influenza
avian
influenza
respiratori
syncyti
viru
adenoviru
parainfluenza
viru
sarscov
merscov
use
realtim
rtpcr
assay
approv
china
food
drug
administr
routin
bacteri
fungal
examin
also
perform
given
emerg
pneumonia
case
influenza
season
antibiot
oral
intraven
osel
tamivir
oral
mg
twice
daili
empir
administ
corticosteroid
therapi
evid
studi
human
coronavirus
includ
caus
mild
respiratori
diseas
fatal
coronaviru
infect
emerg
past
two
decad
sever
acut
respiratori
syndrom
coronaviru
sarscov
middl
east
respiratori
syndrom
coronaviru
search
pubm
china
nation
knowledg
infrastructur
databas
articl
publish
jan
use
keyword
novel
coronoviru
novel
coronaviru
publish
work
human
infect
caus
novel
coronaviru
could
identifi
report
epidemiolog
clinic
laboratori
radiolog
characterist
treatment
clinic
outcom
laboratoryconfirm
case
infect
patient
histori
direct
exposur
huanan
seafood
market
median
age
patient
year
iqr
patient
underli
diseas
patient
pneumonia
third
patient
admit
intens
care
unit
six
die
high
concentr
cytokin
record
plasma
critic
ill
patient
infect
implic
avail
evid
caus
cluster
fatal
pneumonia
clinic
present
greatli
resembl
sarscov
patient
infect
might
develop
acut
respiratori
distress
syndrom
high
likelihood
admiss
intens
care
might
die
cytokin
storm
could
associ
diseas
sever
effort
made
know
whole
spectrum
pathophysiolog
new
diseas
methylprednisolon
mg
per
day
given
combin
regimen
sever
communityacquir
pneumonia
diagnos
physician
design
hospit
oxygen
support
eg
nasal
cannula
invas
mechan
ventil
administ
patient
accord
sever
hypoxaemia
repeat
test
done
patient
confirm
infect
show
viral
clearanc
hospit
discharg
discontinu
isol
review
clinic
chart
nurs
record
laboratori
find
chest
xray
patient
laboratoryconfirm
infect
report
local
health
author
admiss
data
patient
dec
jan
epidemiolog
clinic
laboratori
radiolog
characterist
treatment
outcom
data
obtain
standardis
data
collect
form
modifi
case
record
form
sever
acut
respiratori
infect
clinic
characteris
share
intern
sever
acut
respiratori
emerg
infect
consortium
electron
medic
record
two
research
also
independ
review
data
collect
form
doubl
check
data
collect
ascertain
epidemiolog
symptom
data
avail
electron
medic
record
research
also
directli
commun
patient
famili
ascertain
epidemiolog
symptom
data
characteris
effect
coronaviru
product
cytokin
chemokin
acut
phase
ill
plasma
cytokin
chemokin
also
known
eotaxin
also
known
basic
gcsf
gmcsf
pdgfb
rant
vegfa
measur
use
human
cytokin
standard
assay
panel
bioplex
system
biorad
hercul
ca
usa
patient
accord
manufactur
instruct
plasma
sampl
four
healthi
adult
use
control
crosscomparison
median
time
transfer
design
hospit
blood
sampl
collect
day
iqr
plasma
sampl
patient
contact
ad
trizol
ls
thermo
fisher
scientif
carlsbad
ca
usa
biosafeti
level
laboratori
total
rna
extract
directzol
rna
miniprep
kit
zymo
research
irvin
ca
usa
accord
manufactur
instruct
elut
obtain
sampl
rna
use
realtim
rtpcr
target
np
gene
use
agpathid
onestep
rtpcr
reagent
thermo
fisher
scientif
final
reaction
mix
concentr
primer
nm
probe
nm
realtim
rtpcr
per
form
use
follow
condit
min
min
cycl
amplif
sinc
perform
test
detect
infecti
viru
blood
avoid
term
viraemia
use
rnaaemia
instead
rnaaemia
defin
posit
result
realtim
rtpcr
plasma
sampl
acut
respiratori
distress
syndrom
ard
shock
defin
accord
interim
guidanc
novel
coronaviru
hypoxaemia
defin
arteri
oxygen
tension
inspiratori
oxygen
fraction
less
mm
hg
acut
kidney
injuri
identifi
classifi
basi
highest
serum
creatinin
level
urin
output
criteria
accord
kidney
diseas
improv
global
outcom
classif
secondari
infect
diagnos
patient
clinic
symptom
sign
nosocomi
pneumonia
bacteraemia
combin
posit
cultur
new
pathogen
lower
respiratori
tract
specimen
includ
sputum
transtrach
aspir
bronchoalveolar
lavag
fluid
blood
sampl
taken
h
admiss
cardiac
injuri
follow
definit
use
previou
studi
patient
brief
cardiac
injuri
diagnos
serum
level
cardiac
biomark
eg
troponin
percentil
upper
refer
limit
new
abnorm
shown
electrocardiographi
echocardiographi
continu
variabl
express
median
iqr
compar
mannwhitney
u
test
categor
variabl
express
number
compar
test
fisher
exact
test
icu
care
icu
care
group
boxplot
drawn
describ
plasma
cytokin
chemokin
concentr
twosid
less
consid
statist
signific
statist
analys
done
use
sa
softwar
version
unless
otherwis
indic
funder
studi
role
studi
design
data
collect
data
analysi
data
interpret
write
report
correspond
author
full
access
data
studi
final
respons
decis
submit
public
jan
admit
hospit
patient
identifi
laboratoryconfirm
infect
wuhan
patient
age
year
age
year
figur
median
age
patient
year
iqr
tabl
cohort
first
patient
jan
children
adolesc
infect
patient
admit
icu
requir
highflow
nasal
cannula
higherlevel
oxygen
support
measur
cor
rect
hypoxaemia
infect
patient
men
symptom
onset
date
first
patient
identifi
dec
none
famili
member
develop
fever
respiratori
symptom
epidemiolog
link
found
first
patient
later
case
first
fatal
case
continu
exposur
market
admit
hospit
histori
fever
cough
dyspnoea
day
ill
onset
wife
woman
known
histori
exposur
market
also
present
pneumonia
hospitalis
isol
ward
common
symptom
onset
ill
fever
patient
normal
serum
level
procalcitonin
admiss
procalcitonin
ngml
patient
tabl
four
icu
patient
develop
secondari
infect
three
four
patient
secondari
infect
procalcitonin
greater
ngml
ngml
ngml
ngml
admiss
abnorm
chest
ct
imag
detect
among
patient
patient
bilater
involv
tabl
typic
find
chest
ct
imag
icu
patient
admiss
bilater
multipl
lobular
subsegment
area
consolid
figur
repres
chest
ct
find
nonicu
patient
show
bilater
groundglass
opac
subseg
mental
area
consolid
figur
later
chest
ct
imag
show
bilater
groundglass
opac
wherea
consolid
resolv
figur
initi
plasma
basic
fgf
gcsf
gmcsf
pdgf
vegf
concentr
higher
icu
patient
nonicu
patient
healthi
adult
appendix
pp
plasma
level
eotaxin
rant
similar
healthi
adult
patient
infect
comparison
icu
nonicu
patient
show
plasma
concentr
gcsf
higher
icu
patient
nonicu
patient
patient
pneumonia
tabl
invas
mechan
ventil
requir
four
patient
two
refractori
hypoxaemia
receiv
extracorpor
membran
oxygen
salvag
therapi
patient
administ
empir
antibiot
treatment
patient
receiv
antivir
therapi
osel
tamivir
addit
nine
patient
given
systemat
corticosteroid
comparison
clinic
featur
patient
receiv
receiv
systemat
corticosteroid
appendix
pp
jan
patient
di
charg
six
patient
die
fit
discharg
base
abat
fever
least
day
improv
chest
radiograph
evid
viral
clearanc
respiratori
sampl
upper
respiratori
tract
report
cohort
patient
laboratoryconfirm
infect
patient
seriou
sometim
fatal
pneumonia
admit
design
hospit
wuhan
china
jan
clinic
present
greatli
resembl
sarscov
patient
sever
ill
develop
ard
requir
icu
admiss
oxygen
therapi
time
hospit
admiss
ard
short
day
stage
mortal
rate
high
six
patient
cohort
die
number
death
rise
quickli
jan
laboratoryconfirm
infec
tion
report
china
fatal
case
report
releas
export
case
mani
provinc
china
countri
see
onlin
appendix
healthcar
worker
also
infect
wuhan
taken
togeth
evid
far
indic
human
transmiss
concern
could
acquir
abil
effici
human
tran
mission
airborn
precaut
fittest
respir
person
protect
equip
strongli
recommend
prevent
spread
diseas
healthcar
set
care
patient
infect
onset
fever
respiratori
symptom
close
moni
tore
among
healthcar
worker
test
respiratori
specimen
done
immedi
diagnosi
suspect
serum
antibodi
test
among
healthcar
worker
exposur
identif
asymp
tomat
infect
similar
clinic
featur
previou
betacoronaviru
infect
note
cohort
patient
present
fever
dri
cough
dyspnoea
bilater
groundglass
opac
chest
ct
scan
featur
infect
bear
resembl
sarscov
merscov
infect
howev
patient
infect
promin
upper
respiratori
tract
sign
symptom
eg
rhinorrhoea
sneez
sore
throat
indic
target
cell
might
locat
lower
airway
furthermor
patient
rare
develop
intestin
sign
symptom
eg
diarrhoea
wherea
patient
merscov
sarscov
infect
diarrhoea
faecal
urin
sampl
test
exclud
potenti
altern
rout
transmiss
unknown
stage
pathophysiolog
unusu
high
pathogen
sarscov
merscov
complet
understood
earli
studi
shown
increas
amount
proinflammatori
cytokin
serum
eg
associ
pulmonari
inflamm
extens
lung
damag
sar
patient
merscov
infect
also
report
induc
increas
concentr
proinflammatori
cytokin
note
patient
infect
also
high
amount
probabl
lead
activ
cell
respons
moreov
patient
requir
icu
admiss
higher
concentr
gcsf
requir
icu
admiss
suggest
cytokin
storm
associ
diseas
sever
howev
infect
also
initi
increas
secret
cytokin
eg
suppress
inflamm
differ
sarscov
infect
studi
necessari
characteris
respons
infect
elucid
pathogenesi
autopsi
biopsi
studi
would
key
understand
diseas
view
high
amount
cytokin
induc
sarscov
merscov
infect
corticosteroid
use
frequent
treatment
patient
sever
ill
possibl
benefit
reduc
inflammatoryinduc
lung
injuri
howev
current
evid
patient
sar
mer
suggest
receiv
corticosteroid
effect
mortal
rather
delay
viral
clearanc
therefor
corticosteroid
routin
given
system
accord
interim
guidanc
among
cohort
laboratoryconfirm
patient
infect
corticosteroid
given
nonicu
case
lowtomoder
dose
corticosteroid
given
less
half
sever
ill
patient
ard
evid
urgent
need
assess
whether
systemat
corticosteroid
treatment
benefici
harm
patient
infect
antivir
treatment
coronaviru
infect
proven
effect
histor
control
studi
combin
lopinavir
ritonavir
among
sarscov
patient
associ
substanti
clinic
benefit
fewer
advers
clinic
outcom
arabi
colleagu
initi
placebocontrol
trial
interferon
lopinavir
ritonavir
among
patient
mer
infect
saudi
arabia
preclin
evid
show
potent
efficaci
remdesivir
broadspectrum
antivir
nucleotid
prodrug
treat
merscov
sarscov
infect
emerg
viru
effect
treatment
develop
diseas
result
viru
sinc
combin
lopinavir
ritonavir
alreadi
avail
design
hospit
randomis
control
trial
initi
quickli
assess
efficaci
safeti
combin
use
lopinavir
ritonavir
patient
hospitalis
infect
studi
limit
first
patient
diagnosi
confirm
lower
respiratori
tract
specimen
pair
nasopharyng
swab
obtain
investig
differ
viral
rna
detect
rate
upper
lower
respiratori
tract
specimen
serolog
detect
done
look
antibodi
rise
patient
undetect
viral
rna
second
limit
number
case
difficult
assess
host
risk
factor
diseas
sever
mortal
multivariableadjust
method
modests
case
seri
patient
admit
hospit
collect
standardis
data
larger
cohort
would
help
defin
clinic
present
natur
histori
risk
factor
studi
outpati
primari
care
commun
set
need
get
full
pictur
spectrum
clinic
sever
time
find
statist
test
p
valu
interpret
caution
nonsignific
p
valu
necessarili
rule
differ
icu
nonicu
patient
third
sinc
caus
pathogen
identifi
kinet
viral
load
antibodi
titr
avail
final
potenti
exposur
bia
studi
might
account
paediatr
adolesc
patient
report
cohort
effort
made
answer
question
futur
studi
sarscov
merscov
believ
origin
bat
infect
transmit
directli
human
market
civet
dromedari
camel
respect
extens
research
sarscov
merscov
driven
discoveri
mani
sarslik
merslik
coronavirus
bat
ge
colleagu
report
whole
genom
sequenc
sarslik
coronaviru
bat
abil
use
human
receptor
thu
replic
potenti
human
cell
still
need
studi
deepli
case
becom
global
health
threat
reliabl
quick
pathogen
test
feasibl
differenti
diagnosi
base
clinic
descript
crucial
clinician
first
contact
suspect
patient
pandem
potenti
care
surveil
essenti
monitor
futur
host
adapt
viral
evolut
infect
transmiss
pathogen
bc
jw
idea
design
studi
full
access
data
studi
take
respons
integr
data
accuraci
data
analysi
ywa
gf
xg
jixu
hl
bc
contribut
write
report
bc
contribut
critic
revis
report
ywa
gf
xg
jixu
hl
contribut
statist
analysi
author
contribut
data
acquisit
data
analysi
data
interpret
review
approv
final
version
author
declar
compet
interest
data
support
find
studi
avail
correspond
author
reason
request
particip
data
without
name
identifi
made
avail
approv
correspond
author
nation
health
commiss
public
studi
find
data
avail
other
request
research
team
provid
email
address
commun
data
approv
share
other
propos
detail
descript
studi
object
statist
analysi
plan
need
evalu
reason
request
data
correspond
author
nation
health
commiss
make
decis
base
materi
addit
materi
may
also
requir
process
